A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta

February 6, 2024 updated by: EusaPharma (UK) Limited

A Post-Authorisation Safety Study Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta

This is a non-interventional, multi-national, observational, prospective patient registry to further evaluate the effectiveness and safety of dinutuximab beta - a monoclonal immunoglobulin G 1 (IgG1) antibody, to obtain information on survival, pain severity and incidence of neuro-toxicity, visual impairment, capillary leak syndrome, cardiovascular events, hypersensitivity reactions and long-term safety.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Rationale and Background:

Neuroblastoma, is the most common extra-cranial solid tumour in children. Most patients with neuroblastoma are diagnosed under the age of 5 years and most present with metastatic disease and/or high-risk features. Despite the introduction of novel treatment strategies, including high-dose chemotherapy followed by autologous stem cell transplantation (ASCT), the outcome of these patients remains poor.

Dinutuximab beta is a chimeric monoclonal immunoglobulin G 1 (IgG1) antibody that is specifically directed against the carbohydrate moiety of disialoganglioside antigen (GD2), which is overexpressed on neuroblastoma cells. By binding to neuroblastoma cells, dinutuximab beta can induce both complement dependent cytotoxicity (CDC) and antibody dependent cell-mediated cytotoxicity (ADCC).

The efficacy of dinutuximab beta has been evaluated in a randomised controlled trial comparing the administration of dinutuximab beta with or without interleukin 2 (IL-2) in the first-line treatment of patients with high-risk neuroblastoma and in two singlearm studies in the relapsed/refractory setting. The efficacy and safety of dinutuximab beta will further be evaluated in this registry that will provide information on survival, pain severity and incidence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events, hypersensitivity reactions and long-term safety.

Study Design:

This is a non-interventional, multi-national, observational, prospective patient registry of patients with high-risk neuroblastoma being treated with the monoclonal antibody dinutuximab beta. The efficacy and safety of dinutuximab beta will further be evaluated in this registry that will provide information on survival, pain severity and incidence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events, hypersensitivity reactions and long-term safety.

Research Questions and Objectives:

Primary objectives:

  • To assess pain severity and use of analgesics during the period of first dose of dinutuximab beta to end of last 35 day course of the 5th cycle of treatment
  • To assess the incidence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events and hypersensitivity reactions
  • To assess the long term safety profile

Secondary objectives:

  • Progression free survival (PFS) in patients treated with dinutuximab beta.
  • Event Free Survival (EFS) in patients treated with dinutuximab beta
  • Overall survival (OS) in patients treated with dinutuximab beta

Population:

Patients diagnosed with high-risk neuroblastoma who are starting treatment with dinutuximab beta in the standard clinical practice setting or participating in a clinical trial where dinutuximab beta is provided according to the indication as per the country/regional marketing authorisation, provide consent/assent and are willing to be followed up for up to 10 years.

Study Size:

It is planned to enroll a sufficient number of patients (estimated at 125) such that 100 patients will have completed all five treatment courses of dinutuximab beta. It is anticipated that this will result in 40-50 patients who are progression free at 10 years.

Data Sources:

Data will be collected from physicians using an electronic data capture (EDC) system. The electronic case report forms (eCRFs) will be designed to gather data from the medical records at baseline, during treatment and at normal clinical practice follow up visits.

Data Analysis:

The safety analysis set, containing all patients treated with at least one dose of dinutuximab beta will be considered for safety and efficacy analyses. All baseline, treatment period and follow up characteristics will be summarized using descriptive statistics. Endpoints addressing primary and secondary analysis will include 95% confidence intervals (CIs) including the Clopper Pearson method for binomial, log-log transform for survival. OS, PFS and EFS will be analysed using Kaplan-Meier methods.

Variables:

Baseline (prior to start of treatment): Demographics, clinical trial participation, neuroblastoma disease history, and presence or absence of neurotoxicity, visual impairment, and cardiovascular abnormality.

Treatment period (up to end of last 35 day course of 5th cycle of treatment):

Dosing regimen, total cumulative amount of dinutuximab beta per course, concomitant medications during course (IL-2, retinoic acid and/or antihistamines), daily analgesics (opioids, gabapentin/ pregabalin and/or non-opioid analgesics and other neuropathic pain treatments), daily pain assessment during infusion of dinutuximab beta, occurrence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events, and hypersensitivity reactions, adverse events (AEs)/serious adverse events (SAEs) treatment interruptions and discontinuations, progression of disease, date and cause of death, reason for study withdrawal (if applicable) Follow up (from end of last 35 day course of 5th cycle of treatment): Status of neurotoxicity, visual impairment, cardiovascular events, (resolved, not resolved), SAEs and adverse drug reaction (ADRs), progression of disease, date and cause of death, reason for study withdrawal (if applicable).

Study Type

Observational

Enrollment (Estimated)

125

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Austria
    • Vienna
      • Wien,, Vienna, Austria, 1090
        • Active, not recruiting
        • St. Anna Kinderkrebsforschung
  • France
      • Lille, France, 59000
        • Recruiting
        • Centre Oscar Lambret
        • Contact:
        • Principal Investigator:
          • Anne-Sophie Defachelles, Dr
      • Marseille, France, 13385
        • Recruiting
        • Hôpital de la Timone, Hôpital des Enfants
        • Contact:
          • Sylvie Abed
          • Phone Number: 00 33 4 91 38 68 21
        • Principal Investigator:
          • Carole Coze, Dr
      • Paris, France, 75005
        • Active, not recruiting
        • Institut Curie
      • Villejuif, France, 94805
  • Germany
      • Berlin, Germany, 13353
        • Recruiting
        • Charite Berlin
        • Contact:
        • Contact:
        • Principal Investigator:
          • Angelika Eggert, Dr
        • Sub-Investigator:
          • Heidi Deubzer, Dr
      • Greifswald, Germany, 17475
        • Recruiting
        • Universitätsmedizin Greifswald
        • Contact:
        • Contact:
        • Principal Investigator:
          • Holger Lode, Dr
        • Sub-Investigator:
          • Karoline Ehlert, Dr
  • Italy
      • Genova, Italy, 16147
        • Recruiting
        • IRCCS Istituto Giannina Gaslini
        • Contact:
        • Principal Investigator:
          • Carla Manzitti, Dr
        • Sub-Investigator:
          • Alberto Garaventa, Dr
        • Sub-Investigator:
          • Stefania Sorrentino, Dr
  • Poland
      • Kraków, Poland, 30-663
        • Recruiting
        • Uniwersytecki Szpital Dziecięcy
        • Contact:
        • Contact:
        • Principal Investigator:
          • Aleksandra Wieczorek, Dr
        • Sub-Investigator:
          • Walentyna Balwierz, Dr
        • Sub-Investigator:
          • Urszula Zebrowska, Dr
  • Spain
      • Valencia, Spain, 46026
        • Recruiting
        • Hospital Universitario y Politecnico La Fe Avenida Fernando Abril Martorell
        • Contact:
          • Desiree Ramal
          • Phone Number: +34-638902615
        • Principal Investigator:
          • Adela Canete, Dr
        • Sub-Investigator:
          • Antonio Juan Fornes, Dr
        • Sub-Investigator:
          • Blanca Martinez, Dr
  • United Kingdom
      • Birmingham, United Kingdom, B4 6NH
        • Active, not recruiting
        • Birmingham Children's Hospital
      • Southampton, United Kingdom, so16 6yd
        • Recruiting
        • University Hospital Southampton
        • Contact:
        • Contact:
        • Principal Investigator:
          • Juliet Gray, Dr
        • Sub-Investigator:
          • Sucheta Vaidya, Dr
    • Newcastle
      • Newcastle Upon Tyne, Newcastle, United Kingdom, NE1 4LP
        • Recruiting
        • The Newcastle upon Tyne Hospitals NHS Foundation Trust
        • Contact:
        • Contact:
        • Principal Investigator:
          • Deborah Tweddle, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

2 years to 14 years (Child, Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients diagnosed with high-risk neuroblastoma who are starting treatment with dinutuximab beta in the standard clinical practice setting or participating in a clinical trial where dinutuximab beta is provided according to the indication as per the country/regional marketing authorisation, provide consent/assent and are willing to be followed up for up to 10 years. Centers who treat neuroblastoma patients with dinutuximab beta will be invited to participate in the registry. This includes networks such as the Society of Paediatric Oncology for the Treatment of Neuroblastoma (SIOPEN) in Europe.

Description

Inclusion Criteria:

Patients meeting the following criteria will be considered for inclusion into the registry:

  • Patients diagnosed with high-risk neuroblastoma and starting treatment with commercially available dinutuximab beta OR
  • Patients diagnosed with high-risk neuroblastoma and starting treatment with dinutuximab beta in a clinical trial where dinutuximab beta is provided according to the country/regional marketing authorisation AND
  • Appropriate consent/assent has been obtained for participation in the registry with a willingness to be followed up for up to 10 years.

Exclusion Criteria:

Patient will not be eligible for inclusion if the following criterion applies:

  • Patients commencing dinutuximab beta within a clinical trial where the product is being provided outside of the country/regional marketing authorisation OR
  • Appropriate consent/assent has not been obtained for participation in the registry or patient/legal representative is not willing for the patient be followed up for up to 10 years.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment of the severity of pain experienced by participants during treatment with dinutuximab beta
Time Frame: First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)
Assessment of pain severity experienced by participants during the period of first dose of dinutuximab beta to the end of last 35 day course of 5th cycle of treatment
First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)
Number of participants using analgesics during treatment with dinutuximab beta
Time Frame: First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)
Use of analgesics during the period of first dose of dinutuximab beta to end of last 35 day course of 5th cycle of treatment
First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)
Incidence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events and hypersensitivity reactions
Time Frame: First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)
Incidence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events and hypersensitivity reactions up to the end of the last 35 day course of 5th cycle of treatment
First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)
Number of participants experiencing serious adverse events (SAEs) and adverse drug reactions (ADRs) during treatment with dinutuximab beta
Time Frame: First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)
Number of participants experiencing serious adverse events (SAEs) and adverse drug reactions (ADRs) following the end of the last 35 day course of 5th cycle of treatment
First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall Survival (OS)
Time Frame: First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)
Overall Survival (OS) following the end of the last 35 day course of 5th cycle of treatment
First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)
Progression free survival (PFS)
Time Frame: First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)
Progression free survival (PFS) following the end of the last 35 day course of 5th cycle of treatment
First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)
Event Free Survival (EFS)
Time Frame: First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)
Event Free Survival (EFS) following the end of the last 35 day course of 5th cycle of treatment
First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

EusaPharma (UK) Limited

Collaborators

United BioSource, LLC

Investigators

  • Study Director: Jose-Luis Garcia, EUSA Pharma (UK) Limited

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 30, 2019

Primary Completion (Estimated)

March 31, 2032

Study Completion (Estimated)

June 15, 2032

Study Registration Dates

First Submitted

January 27, 2020

First Submitted That Met QC Criteria

January 31, 2020

First Posted (Actual)

February 5, 2020

Study Record Updates

Last Update Posted (Actual)

February 7, 2024

Last Update Submitted That Met QC Criteria

February 6, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • EUSA DB 0001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neuroblastoma

Clinical Trials on Data-collection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe